PharVision Advisers’s Vermilion Energy VET Stock Holding History

PharVision Advisers’s Portfolio VET Stock Details VET Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q1	–	Sell	-25,399	Closed	-$212K	–	628
2025 Q4	$212K	Buy	+25,399	New	+$210K	0.11%	512

Other funds holding VET

Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return

Ameriprise Minneapolis, Minnesota $432B AUM 30.22% 1-Year Est. Return

Millennium Management New York $240B AUM 35.51% 1-Year Est. Return

Dimensional Fund Advisors Austin, Texas $481B AUM 30.42% 1-Year Est. Return

VCM

Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM

Mackenzie Financial Toronto Ontario, Ontario, Canada $83.3B AUM 31.19% 1-Year Est. Return

American Century Companies Kansas City, Missouri $194B AUM 35% 1-Year Est. Return

UBS Group Zurich, Switzerland $666B AUM 30.12% 1-Year Est. Return

LAII

LM Asset (IM) Inc Vancouver, British Columbia, Canada $192M AUM 105.88% 1-Year Est. Return

Aegis Financial Mc Lean, Virginia $580M AUM 105.74% 1-Year Est. Return

PharVision Advisers's VET Position: Q1 2026 in Review

PharVision Advisers sold out of Vermilion Energy (VET) in Q1 2026, closing a stake of 25,399 shares — an estimated $212K sold.

PharVision Advisers first reported a position in VET in Q4 2025 and held it in 1 quarter. The position peaked at $212K in Q4 2025. 160 funds tracked by Wall St. Rank hold VET as of Q1 2026.

PharVision Advisers reported no remaining Vermilion Energy position as of Q1 2026 after selling out during the quarter.
PharVision Advisers sold 25,399 Vermilion Energy shares in Q1 2026, an estimated $212K.
PharVision Advisers first reported a position in Vermilion Energy in Q4 2025 and held it in 1 quarter.
PharVision Advisers's Vermilion Energy position peaked at $212K in Q4 2025.
160 funds tracked by Wall St. Rank held Vermilion Energy as of Q1 2026.

Based on PharVision Advisers's 13F filing for Q1 2026, filed 22 Apr 2026.